For health systems, the imperative is no longer whether to adopt advanced technology — it is how to deploy it strategically ...

The Cambridge-based R and D company will now finalize designs as it moves to break ground on the project by the end of the ...

RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve ...